Uzedy’s wholesale acquisition cost (WAC) ranges from $1,232 to $3,080 per month.
Approximately 80% of patients with schizophrenia experience multiple relapses over the first five years of treatment, most commonly due to suboptimal adherence to treatment with oral antipsychotics.
© freshidea - stock.adobe.com
The FDA has approved two new medications to treat schizophrenia, including one that is also a treatment for bipolar disorder.
The FDA cleared Teva Pharmaceuticalsand MedinCell’s Uzedy (risperidone) extended-release injectable suspension, the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq™, a copolymer technology proprietary to MedinCell that controls the steady release of risperidone, the pharma makers said.
Therapeutic blood concentrations are reached within 6 to 24 hours of a single dose.
Uzedy’s wholesale acquisition cost (WAC) ranges from $1,232 to $3,080 per month depending on dosage strength. Actual costs for individual patients are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply, Teva and MedinCell said.
Approximately 80% of patients with schizophrenia experience multiple relapses over the first five years of treatment, most commonly due to suboptimal adherence to treatment with oral antipsychotics, the pharma makers said. "Each relapse carries a biological risk of loss of function, treatment refractoriness, and changes in brain morphology.”
“Uzedy embodies Teva’s commitment to bringing innovative advances to patients and to providing people living with schizophrenia an important new treatment option that was designed to address certain treatment challenges and may decrease the risk of relapse,” said Richard Francis, President and CEO of Teva.
Additionally, the FDA approved Otsuka America Pharmaceutical and Lundbeck’s new drug application (NDA) for Alify Asimtufii (aripiprazole) for both schizophrenia and maintenance monotherapy treatment of bipolar I disorder in adults. The extended-release injectable suspension is used once every two months, the pharmaceutical manufacturers said.
The long-acting injectable provides continuous delivery of medication and can maintain therapeutic plasma concentrations, which may help those living with schizophrenia and bipolar I disorder, the companies said.
“This approval is important news for patients, families, and healthcare providers. We hope that the use of Abilify Asimtufii in treatment plans will have a positive impact on those living with schizophrenia or bipolar I disorder,” said Johan Luthman, executive vice president of R&D for Lundbeck.
The medication includes a boxed warning noting that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death and that it is not approved for the treatment of patients with dementia-related psychosis. Abilify Asimtufii is contraindicated with a known hypersensitivity reaction to aripiprazole.
The aripiprazole concentrations of Abilify Asimtufii were explored in a pharmacokinetic bridging study which was a 32-week, open-label, multiple-dose, randomized, parallel-arm, multicenter study in patients living with schizophrenia and bipolar I disorder, according to Otsuka and Lundbeck.
The companies did not respond to Formulary Watch’s requests for comment.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More